Northbrook, Illinois – September 05, 2026 -- Kalohexis, Inc. has appointed Garry Menzel, Ph.D., to its Board of Directors, adding an executive who raised more than $500 million while leading oncology company TCR2 Therapeutics before its 2023 merger with Adaptimmune.

Raleigh, N.C. – September 04, 2026 -- RedHill Biopharma Ltd. (Nasdaq: RDHL) has acquired exclusive global commercialization rights to Ferring Pharmaceuticals' Rebyota and exclusive U.S. rights to Clenpiq, two FDA-approved gastrointestinal drugs that together generated approximately $37.5 million in 2025 net sales.

Uppsala, Sweden – September 04, 2026 -- Orexo AB has reached a non-binding agreement in principle with the US Department of Justice to pay USD 4 million in installments over several years, closing a federal investigation that began in 2020.

Uppsala, Sweden – September 04, 2026 -- Orexo AB has struck a non-binding agreement in principle with the US Department of Justice to settle a federal investigation that has run since 2020, the Swedish pharmaceutical company said.

STOCKHOLM – September 04, 2026 -- Canada's Drug Agency (CDA-AMC) has issued a final recommendation supporting public reimbursement of Leqembi (lecanemab) for patients with mild cognitive impairment or mild dementia due to early Alzheimer's disease, BioArctic AB's partner Eisai announced.

Sydney – September 04, 2026 -- Kazia Therapeutics Limited (NASDAQ: KZIA) has closed an oversubscribed, tranched public offering that generated approximately $40 million in upfront gross proceeds, with total potential proceeds reaching approximately $120 million if milestone-linked warrants are fully exercised.

Dublin – September 03, 2026 -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) reported that Ziihera (zanidatamab-hrii) plus chemotherapy achieved a statistically significant and clinically meaningful overall survival benefit over trastuzumab plus chemotherapy in first-line treatment of HER2-positive advanced gastroesophageal adenocarcinoma (GEA), based on a second interim analysis of the Phase 3 HERIZON-GEA-01 trial.

INDIANAPOLIS – September 03, 2026 -- Eli Lilly and Company reported that combining Taltz (ixekizumab) with Zepbound (tirzepatide) sustained or deepened efficacy at 52 weeks in patients with psoriatic disease and obesity, building on statistically superior results already seen at Week 36 versus Taltz alone.

Dublin – September 03, 2026 -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) reported that Ziihera (zanidatamab-hrii) combined with chemotherapy produced a statistically significant and clinically meaningful overall survival (OS) benefit versus trastuzumab plus chemotherapy in a second interim analysis of the Phase 3 HERIZON-GEA-01 trial in first-line HER2-positive gastroesophageal adenocarcinoma (GEA).

Hong Kong – September 03, 2026 -- Ascletis Pharma Inc. has dosed the first participant in a global Phase III program for ASC30, an oral small molecule GLP-1 receptor agonist for chronic weight management, the Hong Kong Stock Exchange-listed biotech confirmed.